Status:
COMPLETED
Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma
Lead Sponsor:
Xu Yong, MD
Conditions:
Liver Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
To evaluate whether tracking changes in key blood markers over time, together with clinical features, can improve the prediction of outcomes in patients with hepatocellular carcinoma (HCC). By develop...
Detailed Description
This study retrospectively analyzed patients with advanced hepatocellular carcinoma (HCC) who were treated at Shenzhen Third People's Hospital between 2018 and 2024. Eligible participants received sys...
Eligibility Criteria
Inclusion
- pathologically or radiologically confirmed HCC;
- availability of pre- treatment clinical record, radiological and hematological data and more than 2 cycles of post-treatment data;
- receipt of treatment during the study period;
- Age rather than 18 years old.
Exclusion
- baseline data missed;
- Non-primary liver cancer;
- incomplete follow-up data;
- Unevaluable lesions.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2024
Estimated Enrollment :
379 Patients enrolled
Trial Details
Trial ID
NCT07204262
Start Date
January 1 2018
End Date
November 1 2024
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China, 518112